
Dr. Aoife Brennan, President & CEO of Synlogic Therapeutics
Growth & Failure
Rare Disease Innovation Unit at Biogin
The former head of rare disease innovation at biogin is now president in co of sin logic. What encouraged him to leave the company and join sonagi? And if you could describe what sinlogic is happy to so bi thall end the time, i probably would have stayed at bigen If they had continued to pursuit te rare disease focus strategy.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.